Pharmacokinetic analysis of omomyc shows lasting structural integrity and long terminal half-Life in tumor tissue
Beaulieu, Marie-Eve (Peptomyc SL)
Martínez-Martín, Sandra (Peptomyc SL)
Kaur, Jastrinjan (Vall d'Hebron Institut d'Oncologia)
Castillo Cano, Virginia (Peptomyc SL)
Massó Vallés, Daniel (Peptomyc SL)
Foradada Felip, Laia (Peptomyc SL)
López-Estévez, Sergio (Peptomyc SL)
Serrano del Pozo, Erika (Vall d'Hebron Institut d'Oncologia)
Thabussot, Hugo (Peptomyc SL)
Soucek, Laura (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular)

Fecha:	2023
Resumen:	MYC is an oncoprotein causally involved in the majority of human cancers and a most wanted target for cancer treatment. Omomyc is the best-characterized MYC dominant negative to date. In the last years, it has been developed into a therapeutic miniprotein for solid tumor treatment and recently reached clinical stage. However, since the in vivo stability of therapeutic proteins, especially within the tumor vicinity, can be affected by proteolytic degradation, the perception of Omomyc as a valid therapeutic agent has been often questioned. In this study, we used a mass spectrometry approach to evaluate the stability of Omomyc in tumor biopsies from murine xenografts following its intravenous administration. Our data strongly support that the integrity of the functional domains of Omomyc (DNA binding and dimerization region) remains preserved in the tumor tissue for at least 72 hours following administration and that the protein shows superior pharmacokinetics in the tumor compartment compared with blood serum.
Ayudas:	European Commission 872212 Ministerio de Ciencia e Innovación RTC2019-007067-1
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Materia:	Protein therapeutics ; MYC ; Omomyc ; Mass spectrometry ; LC-PRM
Publicado en:	Cancers, Vol. 15, Issue 3 (February 2023) , art. 826, ISSN 2072-6694

DOI: 10.3390/cancers15030826
PMID: 36765784

10 p, 912.2 KB

El registro aparece en las colecciones:
Artículos > Artículos de investigación
Artículos > Artículos publicados